This is a open-label, dose escalation, accelerated titration combined 3+3 design, phase I
study, to evaluate the safety and tolerability, and to determine the RP2D of TR64 when
administered qd in patients with advanced solid tumors. Up to 6 cohorts of 1-6 or 3-6
patients each will be treated in the study.